NDC 80425-0017-01 - Cyclobenzaprine HCL
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 80425-0017
- Requested NDC
- 80425-0017-01
- Package NDCs from labels
- 80425-0017-1, 80425-0017-01
- Manufacturer
- Advanced Rx of Tennessee, LLC
- Effective date
- 2024-12-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cyclobenzaprine HCL - Advanced Rx of Tennessee, LLC | Advanced Rx of Tennessee, LLC | 2024-12-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 80425-0017-1 | Cyclobenzaprine HCL | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 80425-0017 | CYCLOBENZAPRINE HCL TABLET, FILM COATED [ADVANCED RX OF TENNESSEE, LLC] | 5 | Current NDC, Legacy NDC, 1 package rows | 20250101_afca2a49-6424-7b6a-e053-2a95a90ad41e.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 80425-0017-1 | EA - Each | 80425-0017 | 491a6f20-f080-42a3-a5d9-b83a2b908e2e | 1 | 2023-03-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Advanced Rx of Tennessee, LLC | 30ca08c7-4ee3-2f37-e063-6294a90ae31a | 2025-03-20 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Jubilant Cadista Pharmaceuticals Inc. | 592871f6-0eb2-4624-9e10-bd8bf767c002 | 2025-02-21 | Warnings, Adverse reactions | ANDA077563 59746-211 828299 828320 828348 a18ba005-b6de-4c5b-a837-489d74022084 592871f6-0eb2-4624-9e10-bd8bf767c002 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Rising Pharma Holdings, Inc. | 6018b6e9-938d-4fc9-86d7-1fd1d7bfcc58 | 2025-02-20 | Warnings, Adverse reactions | 828320 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Upsher-Smith Laboratories, LLC | 14f64ceb-ea5c-4d7c-a0c1-3f6a64847290 | 2025-02-20 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | aa29e260-fb77-415a-a505-3230d30c8945 | 2025-02-10 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | fbd38abb-02ae-1a36-e053-6294a90abe65 | 2025-02-04 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 418e3974-f7dd-4f27-bee5-3c2fb0531c4c | 2025-02-03 | Warnings, Adverse reactions | 828299 828320 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 05641925-7b10-4b30-b6e8-44b416a5e77e | 2025-02-03 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 96207b29-033b-46a3-961f-e5125288d50f | 2025-02-03 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug, Inc. | 09d0e2fc-76a4-bb7d-e063-6394a90a4a7d | 2025-01-23 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug | fc61c9f5-b0ec-3ff8-e053-6394a90adeb7 | 2025-01-23 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug | 09d35c34-11fa-3a5d-e063-6294a90ab172 | 2025-01-23 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL ER | Direct_Rx | e4a3383a-7b30-25b7-e053-2995a90a341b | 2025-01-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL ER | Direct_Rx | ed0b9acc-132f-64c0-e053-2995a90a198c | 2025-01-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DirectRx | ceb56ab8-4a76-6dee-e053-2995a90aab30 | 2025-01-20 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DIRECT RX | a58cf759-048b-6740-e053-2a95a90a8b43 | 2025-01-17 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DIRECT RX | a512d34c-8164-0c04-e053-2995a90a1942 | 2025-01-17 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 01e18825-1cf9-a98c-e063-6294a90ae0a4 | 2025-01-14 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 3dd2bde1-f06d-493a-91c7-22b28a5e1699 | 2025-01-07 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE | EXELAN PHARMACEUTICALS, INC. | cf81da00-7c6d-4477-bb70-b3c2abea177a | 2025-01-01 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.